Irhythm Technologies Inc (NASDAQ:IRTC) has been given a consensus rating of “Hold” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $67.67.

A number of brokerages recently weighed in on IRTC. Zacks Investment Research raised shares of Irhythm Technologies from a “sell” rating to a “buy” rating and set a $58.00 target price for the company in a research note on Wednesday, October 4th. BidaskClub raised shares of Irhythm Technologies from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. ValuEngine raised shares of Irhythm Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, October 21st. Dougherty & Co began coverage on shares of Irhythm Technologies in a research note on Friday, December 1st. They set a “neutral” rating for the company. Finally, Morgan Stanley lifted their target price on shares of Irhythm Technologies from $50.00 to $65.00 and gave the stock an “overweight” rating in a research note on Friday, November 3rd.

Shares of Irhythm Technologies (IRTC) traded up $2.19 during midday trading on Friday, reaching $65.42. 194,934 shares of the company were exchanged, compared to its average volume of 219,147. Irhythm Technologies has a fifty-two week low of $29.64 and a fifty-two week high of $65.53. The company has a market capitalization of $1,500.00 and a P/E ratio of -54.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.65 and a quick ratio of 7.57.

Irhythm Technologies (NASDAQ:IRTC) last announced its earnings results on Wednesday, November 1st. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.05. Irhythm Technologies had a negative net margin of 27.56% and a negative return on equity of 27.67%. The business had revenue of $25.04 million during the quarter, compared to the consensus estimate of $24.30 million. During the same quarter last year, the firm earned ($2.80) earnings per share. Irhythm Technologies’s quarterly revenue was up 49.2% on a year-over-year basis. analysts anticipate that Irhythm Technologies will post -1.17 earnings per share for the current year.

In other Irhythm Technologies news, Director Vijay K. Lathi sold 150,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $52.57, for a total value of $7,885,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matthew C. Garrett sold 42,910 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $59.17, for a total transaction of $2,538,984.70. Following the completion of the sale, the chief financial officer now owns 36,085 shares of the company’s stock, valued at $2,135,149.45. The disclosure for this sale can be found here. Insiders sold 536,533 shares of company stock valued at $28,333,506 over the last 90 days. Corporate insiders own 23.30% of the company’s stock.

Large investors have recently bought and sold shares of the business. Osterweis Capital Management Inc. acquired a new stake in Irhythm Technologies in the second quarter worth $3,281,000. Employees Retirement System of Texas acquired a new stake in Irhythm Technologies in the second quarter worth $1,742,000. Northern Trust Corp grew its holdings in Irhythm Technologies by 75.7% in the second quarter. Northern Trust Corp now owns 158,910 shares of the company’s stock worth $6,752,000 after purchasing an additional 68,477 shares during the period. Bank of New York Mellon Corp grew its holdings in Irhythm Technologies by 21.5% in the third quarter. Bank of New York Mellon Corp now owns 737,271 shares of the company’s stock worth $38,250,000 after purchasing an additional 130,217 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Irhythm Technologies by 9,692.8% in the third quarter. JPMorgan Chase & Co. now owns 313,371 shares of the company’s stock worth $16,220,000 after purchasing an additional 310,171 shares during the period. Institutional investors and hedge funds own 97.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Irhythm Technologies Inc (IRTC) Receives $67.67 Consensus Price Target from Brokerages” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://theolympiareport.com/2018/01/23/irhythm-technologies-inc-irtc-receives-67-67-consensus-price-target-from-brokerages.html.

About Irhythm Technologies

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.